Clinical Trial: Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients with Locally Advanced Pancreatic Carcinoma

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06861452) titled 'Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients with Locally Advanced Pancreatic Carcinoma' on Jan. 28.

Brief Summary: RR001, a cell-based gene therapy administered following chemotherapy cycles for the treatment of patients with locally advanced pancreatic cancer. Phase I /IIa clinical trial (open label and non-randomized) to test the effects (safety & efficacy) of increasing doses of RR001

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Locally Advanced Pancreatic Adenocarcinoma

Intervention: DRUG: RR001

RR001, a cell-based gene therapy administered following administrati...